U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic

Influenza and other Respiratory Viruses

Volumn 6, Issue 6, 2012, Pages

  Borders Hemphill, Vicky ^a   Mosholder, Andrew ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Antiviral; H1N1; Influenza; Surveillance

Indexed keywords

AMANTADINE; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

2009 H1N1 INFLUENZA; ANTIVIRAL ACTIVITY; ARTICLE; BILLING AND CLAIMS; CONTROLLED STUDY; DATA EXTRACTION; DISEASE SURVEILLANCE; DRUG BIOAVAILABILITY; HEALTH CARE FACILITY; HEALTH CARE UTILIZATION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; UNITED STATES; YOUNG ADULT; ZANAMIVIR;

EID: 84867732112     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2012.00384.x     Document Type: Article

References (13)

1. U.S. Department of Health & Human Services. Available at http://www.hhs.gov/secretary/phe_swh1n1.html (Accessed 20 April 2010).
2. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm (Accessed 26 October 2010).
3. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/H1N1flu/recommendations.htm (Accessed 19 April 2010).
4. IMS Health. IMS National Sales Perspectives™, 2009, Extracted 4-2010. File: 1004anti.dvr
5. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/ncidod/osr/site/sentinel/surv-sys.htm (Accessed 26 October 2010).
6. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/h1n1flu/65andolder.htm (Accessed 18 May 2010).
7. Roche Laboratories. Tamiflu supply letter. Available at http://www.gene.com/gene/products/information/tamiflu/pdf/TAMIFLU_Supply_letter_09_04_2009.pdf (Accessed 12 May 2010).
8. FDA. Postmarket drug safety information for patients and providers. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm188236.htm (Accessed 14 May 2010).
9. Lovegrove MC, Shehab N, Hales CM, Poneleit K, Crane E, Budnitz DS. Emergency department visits for antiviral adverse events during the 2009 H1N1 influenza pandemic. Public Health Rep 2011; 126:312-317.
10. Urushihara H, Doi Y, Arai M et al. Oseltamivir prescription and regulatory actions vis-à-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database. PLoS One 2011; 6:e28483.
11. Hernández JM, López-Rodas V, Costas E. Antiviral agents: to treat or not to treat? An old dilemma revisited in light of new data from the 2009 influenza A(H1N1) pandemic. J Clin Virol 2010; 49:145-146.
12. U.S. Census Bureau, Population Division. Table 1. Annual estimates of the resident population for the United States, regions, states, and Puerto Rico: April 1, 2000 to July 1, 2009 (NST-EST2009-01). Release Date: December 2009. Available at http://www.census.gov/popest/data/historical/2000s/vintage_2009/index.html (Accessed 17 April 2012).
13. Hsieh YH, Chen KF, Gaydos CA, Rothman RE, Kelen GD. Antiviral prescriptions to U.S. ambulatory care visits with a diagnosis of influenza before and after high level of adamantane resistance 2005-06 season. PLoS ONE 2010; 5:e8945.